Summit Therapeutics (SMMT) BLA for ivonescimab accepted with FDA PDUFA date

Rhea-AI Filing Summary

Summit Therapeutics Inc. reported that the U.S. Food & Drug Administration has accepted for filing its Biologics License Application for ivonescimab. The application seeks approval for ivonescimab combined with chemotherapy to treat patients with epidermal growth factor receptor‑mutated, locally advanced or metastatic non‑squamous non‑small cell lung cancer after tyrosine kinase inhibitor therapy.

The FDA set a Prescription Drug User Fee Act goal action date of November 14, 2026, which is the target date for completing its review. Summit disclosed this milestone via a press release, which is included as an exhibit.

Positive

• FDA BLA acceptance for ivonescimab establishes a formal review path and a PDUFA goal action date of November 14, 2026, marking a major regulatory milestone in a serious lung cancer indication.

Negative

• None.

Insights

Biopharma regulatory and pipeline analyst

FDA acceptance of ivonescimab BLA sets a clear review timeline.

The acceptance of a Biologics License Application for ivonescimab in combination with chemotherapy moves this program into formal FDA review. The indication targets EGFR‑mutated, locally advanced or metastatic non‑squamous non‑small cell lung cancer after tyrosine kinase inhibitor therapy, a defined and serious patient population.

The FDA assigned a PDUFA goal action date of November 14, 2026, giving a specific decision timeline. While clinical data and commercial terms are not detailed here, reaching BLA acceptance is a key regulatory milestone that often follows completion of pivotal studies and can meaningfully affect a company’s future prospects if ultimately approved.

0001599298FALSE00015992982026-01-292026-01-29

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): January 29, 2026

Summit Therapeutics Inc.
(Exact Name of Registrant as Specified in Its Charter)
Delaware			001-36866			37-1979717
(State or Other Jurisdiction of Incorporation)			(Commission File Number)			(IRS Employer Identification No.)
601 Brickell Key Drive, Suite 1000, Miami, FL						33131
(Address of Principal Executive Offices)						(Zip Code)

Registrant’s Telephone Number, Including Area Code: (305) 203-2034

Not applicable

(Former Name or Former Address, If Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class			Trading Symbol(s)			Name of Each Exchange on Which Registered
Common stock, $0.01 par value per share			SMMT			The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On January 29, 2026, Summit Therapeutics Inc. (the “Company”) issued a press release announcing that the U.S. Food & Drug Administration (“FDA”) has accepted for filing the Company's Biologics License Application seeking approval for ivonescimab in combination with chemotherapy in patients with epidermal growth factor receptor-mutated locally advanced or metastatic non-squamous non-small cell lung cancer post-tyrosine kinase inhibitor therapy. The FDA provided a Prescription Drug User Fee Act goal action date of November 14, 2026.

A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number			Description
99.1			Press release, dated January 29, 2026
104			Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

			SUMMIT THERAPEUTICS INC.
Date: January 29, 2026			By:			/s/ Manmeet S. Soni
						Chief Operating Officer, Chief Financial Officer and Director
						(Principal Financial Officer)

FAQ

What did Summit Therapeutics Inc. (SMMT) announce in this 8-K filing?

Summit Therapeutics announced that the FDA has accepted for filing its Biologics License Application for ivonescimab plus chemotherapy. The application targets certain EGFR‑mutated non‑small cell lung cancer patients after tyrosine kinase inhibitor therapy, marking a key regulatory milestone for the program.

What is ivonescimab and what condition is Summit (SMMT) targeting?

Ivonescimab is a biologic drug candidate Summit is advancing with chemotherapy for lung cancer. The BLA seeks approval in epidermal growth factor receptor‑mutated, locally advanced or metastatic non‑squamous non‑small cell lung cancer after prior tyrosine kinase inhibitor treatment.

What is the FDA PDUFA action date for Summit’s ivonescimab application?

The FDA assigned a Prescription Drug User Fee Act goal action date of November 14, 2026. This date represents the agency’s target for completing its review of Summit’s Biologics License Application for ivonescimab in the specified lung cancer setting.

Does the Summit Therapeutics 8-K include additional details on ivonescimab?

The 8-K states that further details are provided in a press release attached as Exhibit 99.1. That press release, dated January 29, 2026, is incorporated by reference and is expected to describe the ivonescimab program and regulatory update more fully.

Why is FDA acceptance of a Biologics License Application important for SMMT?

FDA acceptance of a Biologics License Application means the agency has agreed to review the submission. For Summit, this step formally advances ivonescimab toward a potential approval decision and establishes a clear regulatory timeline with the November 14, 2026 PDUFA goal date.